(Q53099775)

11 May 2018

meta-analysis

0 references

title

Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients. (English)

1 reference

11 May 2018

main subject

meta-analysis

0 references

prostatic hypertrophy

1 reference

1 reference

Xiao-Jun Wu

1

1 reference

11 May 2018

Yi Zhi

2

1 reference

11 May 2018

Ji Zheng

3

1 reference

11 May 2018

Peng He

4

1 reference

11 May 2018

Xiao-zhou Zhou

5

1 reference

11 May 2018

Wei-bing Li

6

1 reference

11 May 2018

Zhan-song Zhou

7

1 reference

11 May 2018

language of work or name

English

0 references

publication date

16 November 2013

1 reference

11 May 2018

published in

Urology

1 reference

11 May 2018

volume

83

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

page(s)

539-543

1 reference

11 May 2018

Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Benign prostatic hyperplasia: a progressive disease of aging men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

The role of dihydrotestosterone in benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.007

10.1016/J.UROLOGY.2013.10.007

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018